Optimal Systemic Therapy for Early Female Breast Cancer

This is a clinical practice guideline for female patients who are being considered for or are receiving systemic therapy for early-stage invasive breast cancer. The guideline examines the optimal adjuvant systemic therapy for female patients with early-stage operable breast cancer. Topics of interest include the use of chemotherapy, hormonal therapy, and targeted therapy, as well as patient and disease characteristics, and risk of recurrence.